

# RESEARCH AND IMPLEMENTATION ON DEPRESCRIBING FROM THE VA CENTER FOR MEDICATION SAFETY IN AGING

Kenneth Boockvar, MD & Amy Linsky, MD, MSc

US Deprescribing Research Network

February 4, 2025

# Disclosures

- Grant Support
  - *VA National Center for Patient Safety*
- Dr. Linsky has received speaking and writing fees from NIA and AHRQ for deprescribing-related work



# VA Center for Medication Safety in Aging Framework

- Advance the science of deprescribing
  - National sites
  - Support development & testing of interventions
- Identify barriers/facilitators to inform implementation
- Disseminate deprescribing interventions across VA



# Potentially inappropriate medications: Precursor to deprescribing

- **Risk factors**

- Multiple providers
- Long term care / transitions in care
- Mental health conditions
- Communication / health record lapses

- **Negative consequences**

- Adverse drug events, falls, & mortality
- Decreased quality of life & medication adherence
- Financial burden

Halli-Tierney AD, et al. *Am Fam Physician*. 2019; 100(1): 32-38.



**Veterans Health  
Administration**

# What is Deprescribing?

**Proactive and systematic** process of identifying and **discontinuing drugs** in instances in which existing or potential **harms outweigh** existing or potential **benefits** within the context of an individual patient's care **goals**, current level of **functioning**, life **expectancy**, **values**, and **preferences**.

Scott IA et al. *JAMA Intern Med.* 2015;175(5):827-834.



Veterans Health  
Administration

# ENGAGING PATIENTS TO PROMOTE DEPRESCRIBING

Amy M. Linsky MD, MSc

Katie Fitzgerald Jones, PhD, ACHPN; Kelly Stolzmann, MS;  
Jolie Wormwood, PhD; Jacquelyn Pendergast, BS; Christopher J.  
Miller, PhD; Michael Still, MS; Barbara G. Bokhour, PhD; Joseph  
Hanlon, PharmD, MS; Steven R. Simon, MD; Amy K. Rosen, PhD



*Safer Systems • Safer Care*



**Veterans Health  
Administration**


# VA-adapted EMPOWER brochures



## QUIZ: TRUE OR FALSE

### Gabapentin

1. This medication will reduce pain for everyone who takes it.  True  False
2. This medication is safe and effective, especially at higher doses.  True  False
3. New side effects can appear, even after taking this medication for several years at the same dose.  True  False
4. It can be dangerous to use this medication with opioid pain medicines or alcohol.  True  False



2 You May Be at Risk



# Medication-based cohorts

## Proton Pump Inhibitors (PPIs)

- Current prescription
- $\geq 90$  consecutive days in prior year
- Excluded diagnoses where PPI would be appropriate



Created by Chantrell Boudreau  
from Health Project

## Sulfonylureas/insulin (Hypoglycemia Risk)

- Current prescription
- $\geq 90$  consecutive days in prior year
- Most recent A1c  $< 7\%$
- $> 1$  of the following:
  - age  $> 65$
  - renal insufficiency
  - cog impairment



Created by Lara Messeloberns  
from Health Project

## High Dose Gabapentin

- Current prescription
- $\geq 90$  consecutive days in prior year
- Total daily dose  $> 1800\text{mg}$
- Excluded diagnoses where gabapentin is recommended



Created by Lara Messeloberns  
from Health Project






# Study Design

- Pragmatic quasi-experimental trial
- 3 geographically distinct sites
- Historical Controls:
  - Primary Care Providers' (PCPs) patients before intervention
- PCPs randomized to ordering of patients in medication-based cohorts



# Study Design



# Key variables

- Primary outcomes
  1. Deprescribing 6 months post-intervention (cessation or dose reduction, based on rx data)
  2. Report of deprescribing discussion
- Primary predictor – receipt of intervention
- Patient and clinician characteristics
- Survey responses about deprescribing attitudes and brochure engagement



# Analyses

## 1. Deprescribing at 6 months

- Descriptive statistics
- Hierarchical Generalized Linear Modeling to account for clustering of patients within PCPs within sites

## 2. Deprescribing discussions

- Descriptive statistics
- Sequential model building based on demographics, attitudes, behaviors



# Patient demographics

	Intervention (2,539)	Controls (2,532)	P value
Elixhauser Mortality Index, mean +/- sd	-1.7 +/-8.4	-1.7 +/-8.2	0.96
Age, mean +/- sd	71.1 +/-11.9	70.3 +/-12.7	0.01
Medication Group, n (%)			0.12
PPI	2064 (81.3)	2000 (79.0)	
Gabapentin	97 (3.8)	105 (4.2)	
Diabetes Hypoglycemia	378 (14.9)	427 (16.9)	
Female, n (%)	145 (5.7)	134 (5.3)	0.51
Hispanic/Latino, n (%)	223 (9.3)	200 (8.3)	0.22
Married, n (%)	1235 (49.0)	1297 (51.3)	0.09
Race, n (%)			0.01
Black	326 (14.4)	272 (12.1)	
White	1854 (81.9)	1874 (83.0)	
Hispanic/Other/Multiracial	85 (3.8)	112 (5.0)	



# Deprescribing outcomes

Intervention cohort 29.5% vs. Historical controls 25.8%

	OR	95% CI	p value
Intervention vs Controls	1.205	(1.049,1.383)	0.008
Age	0.999	(0.993,1.005)	0.797
Elixhauser Mortality Index	0.997	(0.988,1.005)	0.451
Female (0/1)	1.203	(0.891,1.626)	0.227
Hispanic (0/1)	1.006	(0.772,1.312)	0.962
Race (reference: White)			0.572
Black	1.12	(0.904,1.387)	
Other	1.051	(0.753,1.467)	
Medication Group (reference: PPI)			0.001
Gabapentin	1.805	(1.313,2.48)	
Diabetes Hypoglycemia	0.896	(0.739,1.087)	
Married (0/1)	0.943	(0.821,1.083)	0.405



# Survey Respondents

- 1,382 (43.1% response rate)
  - White (75%), male (95%), 66-75 years (45%)
  - Lived with other(s) (63%)
  - Adequate health literacy (89%)
- Most (71.3%) engaged with the brochure
  - 29% read it
  - 33% also completed  $\geq 1$  brochure activity
  - 9% also contacted PCP before appointment
- More than half (54%) indicated brochure caused concern



# Deprescribing Discussions

- 29% reported deprescribing discussion
  - 78% indicated they initiated discussion
  - 57% explicitly discussed brochure





# Factors Associated with Discussions

	OR	95% CI
<b>Drug Cohort (ref = PPI)</b>	--	--
DM - Hypoglycemia	0.26	[0.16, 0.40]
Gabapentin	0.61	[0.24, 1.55]
<b>Race/Ethnicity (ref = White)</b>	--	--
Black	0.31	[0.17, 0.57]
Hispanic	0.65	[0.38, 1.13]
Other/Multiracial	0.45	[0.23, 0.86]
<b>Education (ref = high school or less)</b>	--	--
Some College or Vocational School	1.88	[1.29, 2.73]
College Degree	2.11	[1.27, 3.52]
Graduate/Advanced Degree	2.40	[1.35, 4.27]



# Factors Associated with Discussions

	OR	95% CI
<b>Brochure Engagement (ref = none/missing)</b>	--	--
Read Only	1.52	[0.94, 2.45]
Read and Engage Activities	2.23	[1.39, 3.59]
Contact PCP	2.47	[1.34, 4.58]
<b>Discussed with Family/Friends</b>	1.72	[1.22, 2.41]
<b>Discussed with HCP</b>	3.18	[2.08, 4.85]
<b>Elevated Medication Concern</b>	1.50	[1.03, 2.18]
<b>Discussion is Important (ref = low/not at all/missing)</b>	9.11	[6.52, 12.73]
<b>Intend to Deprescribe</b>	1.94	[1.28, 2.94]

*Adjusted for variables in table, and these non-significant variables: age, gender, health status, health literacy, motivation to deprescribe, PCP relationship, healthcare navigation, healthcare ownership*



# Key Points

- Direct-to-patient brochures effectively promote:
  1. Deprescribing
  2. Patient engagement & deprescribing discussions
- Patient engagement is a powerful strategy to implement change in clinical practice
- Low-tech, low-cost intervention with potential for easy dissemination and spread



# TELEPHARMACY MODEL OF CARE

Kristin Phillips, PharmD  
Christine Cigolle, MD, MPH

VA Ann Arbor Healthcare System  
Geriatrics Research, Education, and  
Clinical Center

# Intervention

1. Medication list **accuracy**
2. Assess medication(s) **safety**
3. Assess patient **cognitive** ability
4. Assess patient **health literacy**
5. Assess patient **physical** ability
6. Assess **caregiver** ability to compensate for deficits in #3,4,5

## Red flag

Probably should not be prescribed to older adults

## High risk

Maybe appropriate but higher risk of ADE

Problematic combinations

Complicated Regimens



# Patient Demographics (n=121)

	Number (%)
<b>Age (years, mean)</b>	82.4 years
<b>Marital Status</b>	
Married	73 (60)
Unmarried	48 (40)
<b>Education (years)</b>	
≤12	12 (10)
12	21 (17)
>12	54 (45)
Unknown	34 (28)
<b>Telemedicine Connection</b>	
VA Video Connect (VVC)	69 (57)
Telephone	52 (43)
<b>Pharmacy Personnel Conducting Visit</b>	
PharmD	69 (57)
Pharmacy Technician	52 (43)



# Medication Safety (Steps 1, 2)

- Mean # medications/patient: 11
- Mean # discrepancies/patient: 2.6
  - 41%  $\geq 3$  discrepancies
- 30% with  $\geq 1$  Red Flag medication
- 71% with  $\geq 1$  High Risk medication
- Deprescribing opportunities
  - 68% with  $\geq 1$  deprescribing opportunity (142 meds)
  - 38 (27%) opportunities resulted in deprescribing



# Comprehensive Assessment (Steps 3-6)

- 20% with cognitive and/or health literacy difficulties
- 41% with functional difficulties
- 66% had a caregiver involved





# Key Points

- Address barriers to self-management
- Telemedicine
- Pharmacy technician



# IMPLEMENTATION STRATEGIES FOR DEPRESCRIBING IN OLDER VETERANS AT RISK FOR FALLS


Juliessa Pavon, MD, MHS; Marc Pepin, PharmD; William Bryan, PharmD; Richard Sloane, MPH; Janine Bailey, PharmD; Ivy Ivuoma, RN; Cathleen Colón-Emeric, MD, MHS

# Background

- Falls are harmful and costly, and polypharmacy is a modifiable risk factor
- FAME (Falls Assessment of Medications in the Elderly) is a VA program designed to reduce fall-risk medications
- Aim: to identify an effective, scalable approach



# FAME Intervention Components



# Target Medications and Patients

## Target Med Classes:

Alpha-adrenergic antagonists  
Anticholinergics  
Antidepressants  
Antiepileptics  
Antihyperglycemics  
Antipsychotics  
Benzodiazepines  
Diuretics  
Sedative/hypnotics



DVAHCS veterans  $\geq 65$  yo  
n=18,727




At high risk for falls  
n=9,228



$\geq 1$  fall-related med  
n=6,884



# Results: recommendation acceptance by providers and patients



# Results: effects on drug burden and falls

**At 1 year, FAME patients, compared to controls, had:**

- **Significantly decreased odds of worsening Drug Burden Index: 0.37 [95% CI 0.2-0.6]**
- **Trend for fewer fall-related visits**



# Revised Target Population for Scaling

## Target Med Classes:

Anticholinergics  
Antidepressants  
Antiepileptics  
Antipsychotics  
Benzodiazepines  
Sedative/hypnotics



Durham VAHCS  
Veterans  $\geq 65$  yrs old



At high risk for falls




$\geq 3$  fall-related meds





# Alternative Intervention Strategies to improve scalability



Outcome: Drug Burden Index at 1 year




# Differences in Baseline Characteristics

Patient Group	Control n=85	Strategy 1 n=97	Strategy 2 n=129	Strategy 3 n=110
Age	76.3 (4.6)	75.9 (4.1)	76.8 (3.9)	76.8 (3.4)
Race, White	60 (71%)	71 (73%)	82 (64%)	79 (72%)
<i>Comorbidities</i>				
Anxiety	70 (82%)	69 (71%)	97 (75%)	81 (74%)
Chronic pain	80 (94%)	90 (92%)	120 (93%)	98 (89%)
<b>Cognitive Impairment</b>	4 (5%)	10 (10%)	14 (11%)	24 (22%)
Depression	63 (74%)	66 (68%)	82 (63%)	72 (65%)
<i>Medications each class</i>				
Anticholinergics	72 (85%)	81 (84%)	105 (81%)	99 (90%)
Antidepressants	80 (94%)	93 (96%)	127 (99%)	105 (96%)
<b>Benzodiazepines</b>	30 (35%)	33 (34%)	43 (33%)	15 (13%)
<b>Sedatives</b>	28 (33%)	20 (21%)	21 (16%)	10 (9%)
Average number of FRIDS medications	3.4 (0.6)	3.4 (0.7)	3.3 (0.5)	3.1 (0.3)



# Results by Delivery Strategy




# Results by Delivery Strategy

Odds of increasing Drug Burden Index by  $\geq 0.5$  compared to controls similar across strategies



  
n=97

  
n=129

  
n=110



# Conclusions and implications

- Strategies conferred **lower odds** of worsening drug burden at 1 year
- Program may have more impact on **preventing additional** prescriptions than decreasing existing use.
- **Lower intensity, lower-resource strategies** were as effective as others.



# A BREAKTHROUGH SERIES COLLABORATIVE FOR DEPRESCRIBING ACROSS VA

Kenneth Boockvar, MD

# Breakthrough Series Overview

- Team requirements: readiness, champions, commitment
- Engagement components:
  - Nationwide VA solicitation
  - Presentations from investigators and leaders
  - Small group and 1-to-1 facilitation meetings with shared learning
  - Audit and feedback of standard measures
  - Veteran and Caregiver Council input



# Toolkit

- VIONE – Vital, Important, Optional, Not Indicated
- Direct-to-Patient Deprescribing Materials
- Deprescribing E-consult
- IMPROVE Deprescribing Clinic
- TRIM deprescribing decision-support

Available through VA Sharepoint





# Virtual Breakthrough Series

Journal of Medical Systems (2019) 43:27  
<https://doi.org/10.1007/s10916-018-1126-z>

SYSTEMS-LEVEL QUALITY IMPROVEMENT



## How to do a Virtual Breakthrough Series Collaborative

Lisa Zubkoff<sup>1,2,3</sup> · Julia Neily<sup>3</sup> · Peter D. Mills<sup>2,3</sup>

Received: 21 May 2018 / Accepted: 20 November 2018

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019


### Abstract

Despite widespread use of the breakthrough series (BTS) collaborative in healthcare, there is limited literature on how to operationalize the method in healthcare settings. A recent modification to the model is the virtual breakthrough series (VBTS), in which all work is done remotely via telephone and web-based platforms. With virtual methods gaining popularity, this manuscript presents guidance on methods to conduct a virtual breakthrough series collaborative to assist clinical teams in implementing evidence-based practices. Manuscript describes planning activities and implementation steps for individuals interested in conducting a VBTS collaborative. Topics presented include planning/preparation activities (e.g., developing a planning committee and change package of the evidence-based interventions), estimated resources required (i.e., personnel, percent effort), activities to prepare participants for the project (e.g., orientation calls), specific actions during the virtual collaborative, and evaluation approaches. The manuscript also presents examples from our work and templates for end users. This paper is a first attempt to describe the infrastructure and processes of a VBTS collaborative and offer reproducible methods currently employed in the U.S. Veterans Health Administration.




Veterans Health  
Administration

# Nationwide participation



# Collaborative timeline



# Site and Intervention Characteristics

	n = 21
<b>Practice Area</b>	
Ambulatory Care (including Geriatrics)	11
Home-based primary care	9
Nursing home	5
Other Specialty (Mental Health, Nephrology)	2
<b>Intervention Method</b>	
Decision Support/Population Health tool (VIONE)	15
Direct to Patient Materials (EMPOWER)	1
Intensive Individualized Review (IMPROVE)	1
Other	4



# Veterans served/medications deprescribed

- Total of 8,332 medications deprescribed in 4,770 Veterans (1-2 medications per Veteran)
- Mean 66 Veterans served and 62 medications deprescribed per site per month

	Veterans served per Site	Medications deprescribed per site	Meds deprescribed per Veteran, per site
Cohort	mean (range; SD)	mean (range; SD)	mean (range; SD)
1 (n=12)	204.3 (41-791; 197.4)	276.2 (21-1208; 302.4)	1.3 (0.48-2.52; 0.61)
2 (n=9)	596.9 (1-2713; 864.2)	557.6 (3-1916; 724.1)	1.2 (0.28-3.0; 0.76)



# Barriers

- |  |  |
|--|--|
| <ul style="list-style-type: none"><li>• Staff turnover--difficult to keep up with education</li></ul>              | <ul style="list-style-type: none"><li>• Patients restart or increase target medication due to symptom relapse.</li></ul> |
| <ul style="list-style-type: none"><li>• Difficulty maintaining momentum over time</li></ul>                        | <ul style="list-style-type: none"><li>• Need to show cost-savings to maintain facility support</li></ul>                 |
| <ul style="list-style-type: none"><li>• Hard to intervene on medications prescribed by outside providers</li></ul> | <ul style="list-style-type: none"><li>• Data collection to track progress</li></ul>                                      |







# Facilitators and unanticipated benefits

Support from providers initially uninterested in deprescribing	Providers integrating deprescribing into daily tasks
Adoption of deprescribing outside the initial setting	Increased patient agency related to medication management
<ul style="list-style-type: none"><li>• Adaptable to telepharmacy</li></ul>	<ul style="list-style-type: none"><li>• Some sites saw changes in prescribing patterns</li></ul>

**MODELS OF GERIATRIC CARE, QUALITY  
IMPROVEMENT, AND PROGRAM DISSEMINATION**

---

# **A virtual breakthrough series collaborative to support deprescribing interventions across Veterans Affairs healthcare settings**

**Kristin K. Phillips PharmD<sup>1</sup>  | Marcia C. Mecca MD<sup>2,3</sup>  |  
Abigail M. Baim-Lance PhD<sup>4,5,6</sup>  | Gabrielle S. Schiller MPH<sup>6,7</sup>  |  
Jennifer A. Pruskowski PharmD, MS<sup>8,9,10</sup>  | Elizabeth C. Ellis PharmD<sup>11</sup> |  
Deylen S. Aponte-Rosario PharmD<sup>12</sup> | Amanda L. Federovich-Hogan DNP<sup>8,13</sup> |  
Annette C. Kossifologos PharmD<sup>14</sup> | Erica D. Martinez BA<sup>15</sup> |  
Kenneth S. Boockvar MD, MS<sup>16,17</sup> **





# QUESTION AND ANSWER